Ryan Deschner
Stock Analyst at Raymond James
(4.81)
# 113
Out of 5,182 analysts
20
Total ratings
88.89%
Success rate
72.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Downgrades: Market Perform | n/a | $40.95 | - | 3 | Apr 1, 2026 | |
| PVLA Palvella Therapeutics | Upgrades: Strong Buy | $92 → $143 | $128.64 | +11.16% | 2 | Nov 19, 2025 | |
| TVRD Tvardi Therapeutics | Downgrades: Market Perform | n/a | $3.05 | - | 2 | Oct 14, 2025 | |
| LQDA Liquidia | Maintains: Strong Buy | $33 → $41 | $37.34 | +9.80% | 4 | Aug 13, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Strong Buy | $29 → $27 | $14.27 | +89.21% | 3 | Aug 8, 2025 | |
| ARDX Ardelyx | Maintains: Outperform | $11 → $12 | $5.99 | +100.33% | 2 | Aug 5, 2025 | |
| VKTX Viking Therapeutics | Maintains: Strong Buy | $125 → $122 | $32.99 | +269.87% | 1 | Jul 24, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $7.95 | +252.20% | 3 | Jan 14, 2025 |
Apellis Pharmaceuticals
Apr 1, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $40.95
Upside: -
Palvella Therapeutics
Nov 19, 2025
Upgrades: Strong Buy
Price Target: $92 → $143
Current: $128.64
Upside: +11.16%
Tvardi Therapeutics
Oct 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $3.05
Upside: -
Liquidia
Aug 13, 2025
Maintains: Strong Buy
Price Target: $33 → $41
Current: $37.34
Upside: +9.80%
Trevi Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $27
Current: $14.27
Upside: +89.21%
Ardelyx
Aug 5, 2025
Maintains: Outperform
Price Target: $11 → $12
Current: $5.99
Upside: +100.33%
Viking Therapeutics
Jul 24, 2025
Maintains: Strong Buy
Price Target: $125 → $122
Current: $32.99
Upside: +269.87%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $7.95
Upside: +252.20%